Download NCI60 Cancer Cell Panel

NCI60细胞系列及一些常用数据库
介绍
谢丽
NCI-60细胞系列简介
 自1990年已用于筛选超过100，000个化合物

Developmental Therapeutics Program of the National Cancer Institute
NCI60 screening and secondary testing Nat Rev Cancer 2006
NCI60细胞系列组织来源
 Leukemias
 Melanomas
 Cancers of ovarian
 Cancers of renal
 Cancers of breast
 Cancers of prostate
 Cancers of colon
 Cancers of lung
 Cancers of CNS origin
NCI60 screening and secondary testing
sulforhodamine B assay 测GI50
原理：A means of measuring total
biomass by staining cellular proteins with
the Sulforhodamine B.
检测流程：




清洗细胞
染色
溶解
吸光值测定
基因各个水平的profile已经非常完备
DNA
RNA
Protein
Chromosome
MiRNA
FREE
相关文献




















A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236– 44.
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001; 98:10787–92.
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res
2004;64:4294–301.
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24: 227–35.
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther
2007;6:820–32.
A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997; 18:647–53.
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci
U S A 2003;100:14229–34.
Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array
profiling. Cancer Res 2003;63:5243–50.
Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003;326:909–20.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606–12.
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol
Cancer Ther 2006;5:853–67.
Karyotypic ‘‘state’’ as a potential determinant for anticancer drug discovery. Proc Natl Acad Sci U S A 2005;102:2964–9.
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634–47.
Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol Cancer Ther 2005;4:1559–68.
Spotlight on molecular profiling: ‘‘integromic’’ analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 2006;5:2601–5.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther
2006;5:2613–23.
Predicting Cancer Drug Response by Proteomic Profiling. Clin Cancer Res. 2006 Aug 1;12(15):4583-9.
Prediction of Broad Spectrum Resistance of Tumors towards Anticancer Drugs. Clin Cancer Res. 2008 Apr 15;14(8):2405-12.
Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Mol Cancer Ther. 2007 Feb;6(2):391403.
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007
重要的结论
mRNA表达和蛋白表达水平具有40-70％左
右的相关性
细胞对于药物的敏感性与细胞的组织学来
源关系不大，与细胞的增殖水平有关
一些TCM来源的化合物能够对广谱多药耐
药细胞仍然有效，提示作用机制的多靶点
mRNA profiling比miRNA profiling更好的鉴
别组织来源
DNA copy number
基于NCI-60的基因组合用于预测药物疗效
基于NCI-60的药物靶点预测
从信号通路角度分析DOC敏感性
相关基因
用NCI-60筛选与药物疗效最相关的miRNA
CDH1甲基化
Mutaion